Effectiveness of the methadone programme in the treatment of patients on a mephedrone binge and dependent on heroin: a retrospective study, 2010–19

References

• Amraei M, Mohamadpour M, Ahmadi MRH, Azizi M, Daemi A, Omidi M, Shirzadpour E. 2018. Histopathological study of liver tissue due to methadone consumption and its effect on liver enzymes and inflammatory indices in rat. DDDT. 12:3785–3795. doi:10.2147/DDDT.S182032
   PubMed Web of Science ®Google Scholar
• Back SE, Lawson KM, Singleton LM, Brady KT. 2011. Characteristics and correlates of men and women with prescription opioid dependence. Addict Behav. 36(8):829–834. doi:10.1016/j.addbeh.2011.03.013
   PubMed Web of Science ®Google Scholar
• Bawor M, Dennis BB, Anglin R, Steiner M, Thabane L, Samaan Z. 2014. Sex differences in outcomes of methadone maintenance treatment for opioid addiction: a systematic review protocol. Syst Rev. 3:45. doi:10.1186/2046-4053-3-45
   PubMedGoogle Scholar
• Bawor M, Dennis BB, Bhalerao A, Plater C, Worster A, Varenbut M, Daiter J, Marsh DC, Desai D, Steiner M, et al. 2015. Sex differences in outcomes of methadone maintenance treatment for opioid use disorder: a systematic review and meta-analysis. CMAJ Open. 3(3):E344–E351. doi:10.9778/cmajo.20140089
   PubMedGoogle Scholar
• Bell J, Strang J. 2020. Medication treatment of opioid use disorder. Biol Psychiatry. 87(1):82–88. doi:10.1016/j.biopsych.2019.06.020
   PubMed Web of Science ®Google Scholar
• Caplehorn JR, Dalton MS, Haldar F, Petrenas AM, Nisbet JG. 1996. Methadone maintenance and addicts’ risk of fatal heroin overdose. Subst Use Misuse. 31(2):177–196. doi:10.3109/10826089609045806
   PubMed Web of Science ®Google Scholar
• Chatham LR, Hiller ML, Rowan-Szal GA, Joe GW, Simpson DD. 1999. Gender differences at admission and follow-up in a sample of methadone maintenance clients. Subst Use Misuse. 34(8):1137–1165. doi:10.3109/10826089909039401
   PubMed Web of Science ®Google Scholar
• Des Jarlais DC. 2017. Harm reduction in the USA: the research perspective and an archive to David Purchase. Harm Reduct J. 14(1):51. doi:10.1186/s12954-017-0178-6
   PubMed Web of Science ®Google Scholar
• Dole VP, Nyswander ME. 1967. Heroin addiction–a metabolic disease. Arch Intern Med. 120(1):19–24. doi:10.1001/archinte.1967.00300010021004
   PubMed Web of Science ®Google Scholar
• Donny EC, Brasser SM, Bigelow GE, Stitzer ML, Walsh SL. 2005. Methadone doses of 100 mg or greater are more effective than lower doses at suppressing heroin self-administration in opioid-dependent volunteers. Addiction. 100(10):1496–1509. doi:10.1111/j.1360-0443.2005.01232.x
   PubMed Web of Science ®Google Scholar
• Evans EA, Zhu Y, Yoo C, Huang D, Hser YI. 2019. Criminal justice outcomes over 5 years after randomization to buprenorphine-naloxone or methadone treatment for opioid use disorder. Addiction. 114(8):1396–1404. doi:10.1111/add.14620
   PubMed Web of Science ®Google Scholar
• Faggiano F, Vigna-Taglianti F, Versino E, Lemma P. 2003. Methadone maintenance at different dosages for opioid dependence. Cochrane Database System Rev. 3:CD002208.
   PubMedGoogle Scholar
• Grassi A, Ballardini G. 2017. Hepatitis C in injection drug users: it is time to treat. World J Gastroenterol. 23(20):3569–3571. doi:10.3748/wjg.v23.i20.3569
   PubMed Web of Science ®Google Scholar
• Hahn JA, Page-Shafer K, Lum PJ, Ochoa K, Moss AR. 2001. Hepatitis C virus infection and needle exchange use among young injection drug users in San Francisco. Hepatology. 34(1):180–187. doi:10.1053/jhep.2001.25759
   PubMed Web of Science ®Google Scholar
• Hockenhull J, Murphy KG, Paterson S. 2016. Mephedrone use is increasing in London. Lancet. 387(10029):1719–1720. doi:10.1016/S0140-6736(16)30258-6
   PubMed Web of Science ®Google Scholar
• Hoffman RS. 2000. Is methadone a miracle cure or an alternative evil? West J Med. 172(1):15–16. doi:10.1136/ewjm.172.1.15
   PubMedGoogle Scholar
• Joseph H, Woods JS. 2018. Changing the treatment direction for opiate addiction: Dr. Dole’s Research. Subst Use Misuse. 53(2):181–193. doi:10.1080/10826084.2017.1400069
   PubMed Web of Science ®Google Scholar
• Kwiatkowski CF, Fortuin Corsi K, Boot RE. 2002. The association between knowledge of hepatitis C virus status and risk behaviors in injection drug users. Addiction. 97(10):1289–1294. doi:10.1046/j.1360-0443.2002.00208.x
   PubMed Web of Science ®Google Scholar
• Lavelle S. 2016. Designer drugs and the impact on the adolescent user. Arch Psychiatr Nurs. 30(3):447–448. doi:10.1016/j.apnu.2016.01.009
   PubMed Web of Science ®Google Scholar
• Leshner AI, Dzau VJ. 2019. Medication-based treatment to address opioid use disorder. JAMA. 321(21):2071–2072. doi:10.1001/jama.2019.5523
   PubMed Web of Science ®Google Scholar
• McAuley A, Yeung A, Taylor A, Hutchinson SJ, Goldberg DJ, Munro A. 2019. Emergence of novel psychoactive substance injecting associated with rapid rise in the population prevalence of hepatitis C virus. Int J Drug Policy. 66:30–37. doi:10.1016/j.drugpo.2019.01.008
   PubMed Web of Science ®Google Scholar
• Meyer MC, Johnston AM, Crocker AM, Heil SH. 2015. Methadone and buprenorphine for opioid dependence during pregnancy: a retrospective cohort study. J Addict Med. 9(2):81–86. doi:10.1097/ADM.0000000000000092
   PubMed Web of Science ®Google Scholar
• Miller JL, Ernst K, Neely SB, Stephens K, Barker P, Skrepnek GH, Johnson PN. 2019. Low-dose versus high-dose methadone for the management of neonatal abstinence syndrome. J Opioid Manage. 15(2):159–167.
   PubMedGoogle Scholar
• Moskalewicz J, Welbel M. 2013. Walking through mud; history of the Polish methadone maintenance treatment from its stakeholders’ perspective. Subst Use Misuse. 48(11):977–996. doi:10.3109/10826084.2013.797836
   PubMed Web of Science ®Google Scholar
• Mouly S, Bloch V, Peoc’h K, Houze P, Labat L, Ksouda K, Simoneau G, Declèves X, Bergmann JF, Scherrmann J-M, et al. 2015. Methadone dose in heroin-dependent patients: role of clinical factors, comedications, genetic polymorphisms and enzyme activity. Br J Clin Pharmacol. 79(6):967–977. doi:10.1111/bcp.12576
   PubMed Web of Science ®Google Scholar
• Neicun J, Steenhuizen M, van Kessel R, Yang JC, Negri A, Czabanowska K, Corazza O, Roman-Urrestarazu A. 2019. Mapping novel psychoactive substances policy in the EU: the case of Portugal, the Netherlands, Czech Republic, Poland, the United Kingdom and Sweden. PLoS One. 14(6):e0218011. doi:10.1371/journal.pone.0218011
   PubMed Web of Science ®Google Scholar
• O’Donnell TF, Jackson TL. 2017. Opioid use disorder and pregnancy. Missouri Med. 114(3):181–186.
   PubMedGoogle Scholar
• Ordak M, Nasierowski T, Muszynska E. 2018. The growing problem of mephedrone use in Warsaw, Poland, 2010-18. Lancet Psychiatry. 5(10):787. doi:10.1016/S2215-0366(18)30305-5
   PubMed Web of Science ®Google Scholar
• Ordak M, Nasierowski T, Muszynska E. 2019. The problem of poly-pharmacotherapy in patients on a mephedrone binge. Pharmacol Res. 143:204. doi:10.1016/j.phrs.2019.04.003
   PubMed Web of Science ®Google Scholar
• Salsitz EA, Joseph H, Frank B, Perez J, Richman BL, Salomon N, Kalin MF, Novick DM. 2000. Methadone medical maintenance (MMM): treating chronic opioid dependence in private medical practice–a summary report (1983–1998). Mt Sinai J Med. 67(5–6):388–397.
   PubMedGoogle Scholar
• Salsitz EA, Wiegand T. 2016. Pharmacotherapy of opioid addiction: “putting a real face on a false demon”. J Med Toxicol. 12(1):58–63. doi:10.1007/s13181-015-0517-5
   PubMed Web of Science ®Google Scholar
• Shiu JR, Ensom MH. 2012. Dosing and monitoring of methadone in pregnancy: literature review. Can J Hosp Pharm. 65(5):380–386.
   PubMedGoogle Scholar
• Tarján A, Dudás M, Wiessing L, Horváth G, Rusvai E, Tresó B, Csohá Á. 2017. HCV prevalence and risk behaviours among injectors of new psychoactive substances in a risk environment in Hungary-An expanding public health burden. Int J Drug Policy. 41:1–7. doi:10.1016/j.drugpo.2016.11.006
   PubMed Web of Science ®Google Scholar
• Tiihonen J, Taipale H, Mehtälä J, Vattulainen P, Correll CU, Tanskanen A. 2019. Association of antipsychotic polypharmacy vs monotherapy with psychiatric rehospitalization among adults with schizophrenia. JAMA Psychiatry. 76(5):499–507. doi:10.1001/jamapsychiatry.2018.4320
   PubMed Web of Science ®Google Scholar
• Trafton JA, Minkel J, Humphreys K. 2006. Opioid substitution treatment reduces substance use equivalently in patients with and without posttraumatic stress disorder. J Stud Alcohol. 67(2):228–235. doi:10.15288/jsa.2006.67.228
   PubMed Web of Science ®Google Scholar
• Trujols J, González-Saiz F, Manresa MJ, Alcaraz S, Batlle F, Duran-Sindreu S, Pérez de Los Cobos J. 2017. Patient perception of methadone dose adequacy in methadone maintenance treatment: the role of perceived participation in dosage decisions. Patient Educ Couns. 100(5):981–986. doi:10.1016/j.pec.2016.12.001
   PubMed Web of Science ®Google Scholar
• Volkow ND, Jones EB, Einstein EB, Wargo EM. 2019. Prevention and treatment of opioid misuse and addiction: a review. JAMA Psychiatry. 76(2):208–216. doi:10.1001/jamapsychiatry.2018.3126
   PubMed Web of Science ®Google Scholar
• Wang S. 2019. Historical review: opiate addiction and opioid receptors. Cell Transplant. 28(3):233–238. doi:10.1177/0963689718811060
   PubMed Web of Science ®Google Scholar
• WHO. 2009. Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence. Geneva (Switzerland): World Health Organisation.
   Google Scholar
• Yang J, Li J, Xu G, Zhang J, Chen Z, Lu Z, Deng H. 2016. Elevated hair cortisol levels among heroin addicts on current methadone maintenance compared to controls. PLoS One. 11(3):e0150729. doi:10.1371/journal.pone.0150729
   PubMed Web of Science ®Google Scholar